Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
Lugano (ots) - With reference to the Irish Medicine Board (IMB) decision, mainly based on 6 cases of hepatic damage, to suspend the marketing and sale of nimesulide and following the request to the European Committee for Medicinal Products for Human Use (CHMP) to revise the benefit/risk profile of the drug, Helsinn Healthcare deems opportune to specify that nimesulide is a drug with a positive safety profile as ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV) has been submitted to the U.S. Food and Drug ...
Winterthur (ots) - SpineLab AG, a privately held company, specialized in developing a dynamic stabilization system for the spine, announced today that it has raised CHF 4 million in a first financing round. Lead investors are BioMedInvest and VI Partners. Other participants are the management and Acceleration International. Gérard Moufflet, CEO and Founder of Acceleration International has been appointed Chairman of ...
Berlin (ots) - ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co-promotion. In the first agreement, ProBioGen will apply its proven cell generation process for biopharmaceutical cell ...
Freising-Weihenstephan (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific ...
Zurich (ots) - Prionics, a world leader in farm animal diagnostics, has received approval for the extended use of its Johne's disease test Parachek®. With the original test kit for the diagnosis of paratuberculosis, the United States Department of Agriculture (USDA) has for the first time officially validated ...
Aachen, Germany (ots) - Grünenthal GmbH announced that it has extended a licensing agreement with Ortho-McNeil Pharmaceutical, Inc. for tapentadol to include the Japanese market. Ortho-McNeil Pharmaceutical plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil"s affiliate, ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary ...
Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals Announce World Class Partnership in State of the Art Cancer Therapy Dusseldorf (ots) - ION Boston Management GmbH, which is 50%-owned by Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals, has entered into a Radiology Oncology Associates ...
Freising-Weihenstephan, Germany - (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today that it has confirmed the functional antagonistic activity of its lead PRS-050 Anticalin® in vivo, supporting the development of superior biotherapeutics ...
Freising-Weihenstephan/Germany (ots) - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics Pieris AG, a biopharmaceutical company developing therapeutic products comprising Anticalins®, a novel ...
Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical and protein engineering company exploiting its proprietary Anticalin(r) technology for the development of superior human biotherapeutic and diagnostics products, today announced that it has successfully reached key milestones within its collaboration project with Syngenta. After careful ...
Bensberg (ots) - Girindus, with core competencies in process development, scale up and manufacture of innovative drug and cosmetic actives, sees a significant increase in demand for its commercial oligonucleotide production capabilities in the USA and Europe. "Our know-how and our technical expertise in the area of oligonucleotide research, development and manufacturing has been validated by an increased market ...
Aachen (ots) - Tapentadol would be the first new molecular entity in the class of oral centrally acting analgesics to enter medical practice in over 25 years. At the American Pain Society Meeting in San Antonio, Texas, Grünenthal GmbH presented positive results on preclinical and early clinical studies of ...
21st Annual Meeting of the European Association of Urology (EAU), Paris, 5th - 8th April 2006 Treatment with degarelix results in fast, profound and sustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge Paris (ots) - Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous ...
Lugano/Johannesburg (ots) - HELSINN HEALTHCARE SA, and PFIZER LABORATORIES (PTY) LTD, announce the signing of an agreement granting PFIZER in South Africa, the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by ...
Zürich (ots) - Prionics announced the acquisition of CEDI-Diagnostics. The Dutch firm is a spin-off from the world-famous Wageningen University and Research Centre (Wageningen UR). Through the purchase of CEDI, Prionics will acquire a substantial number of new products and gain rights to commercialize ...
Lugano, Switzerland and Stockholm, Sweden (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and BIOVITRUM AB, a Swedish Biotechnology company, announce the signing of an agreement granting BIOVITRUM the exclusive License and Distribution rights of Aloxi® (Palonosetron hydrochloride) in the NORDIC ...
Lugano (ots) - HELSINN HEALTHCARE SA signed an Agreement with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi® (palonosetron hydrochloride) in France, Belgium, Luxemburg and The Netherlands. Aloxi® is a strong and long-lasting antiemetic belonging to ...
Zurich (ots) - The world leader in prion diagnostics has landed another coup in the fight against animal diseases and consumer protection. Prionics AG will be promoting the use of the innovative diagnostic ear tag TypiFix, which combines individual livestock identification with tissue sampling. "The special mummification technique of TypiFix allows it to easily trace back from the fork to the farm", says ...
Zurich (ots) - Baxter Healthcare S.A. announced today that Baxter"s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Once licensed, ...
Zurich (ots) - Prionics AG, the world leader in prion diagnostics and Pfizer Animal Health, the world's leading animal health company, agreed today that Prionics will acquire Pfizer Animal Health's diagnostic products. Terms were not disclosed. The product line includes tests for the detection of ...
Lugano, Switzerland and Lisboa, Portugal (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the signing of an agreement granting ANGELINI the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in PORTUGAL. ALOXI® is a strong and long acting ...
South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
Biasca, Switzerland (ots) - Helsinn Chemicals SA and Helsinn Advanced Synthesis SA have successfully passed a re-certification audit of its ISO14001 Environmental Management System. The audit by SGS took place on May 2nd and 3rd 2005. In parallel, Helsinn has also applied for an audit from SGS to inspect the Helsinn sites in relation to the Occupational Health and Safety Assessment Series (OHSAS) 18001 ...
Lugano, Switzerland, and Ljulubiana (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and PHARMASWISS, a Pharmaceutical company based in SLOVENIA, announce the signing of an agreement granting PHARMASWISS the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in ...